Coherus Oncology (CHRS) Equity Ratio: 2013-2025
Historic Equity Ratio for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to 0.17.
- Coherus Oncology's Equity Ratio rose 197.55% to 0.17 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.17, marking a year-over-year increase of 197.55%. This contributed to the annual value of -0.29 for FY2024, which is 4.21% up from last year.
- According to the latest figures from Q3 2025, Coherus Oncology's Equity Ratio is 0.17, which was down 37.68% from 0.27 recorded in Q2 2025.
- In the past 5 years, Coherus Oncology's Equity Ratio registered a high of 0.27 during Q2 2025, and its lowest value of -0.49 during Q1 2025.
- For the 3-year period, Coherus Oncology's Equity Ratio averaged around -0.20, with its median value being -0.23 (2023).
- In the last 5 years, Coherus Oncology's Equity Ratio plummeted by 2,406.41% in 2023 and then surged by 318.78% in 2025.
- Over the past 5 years, Coherus Oncology's Equity Ratio (Quarterly) stood at 0.14 in 2021, then slumped by 298.66% to -0.29 in 2022, then decreased by 7.50% to -0.31 in 2023, then grew by 4.21% to -0.29 in 2024, then spiked by 197.55% to 0.17 in 2025.
- Its Equity Ratio stands at 0.17 for Q3 2025, versus 0.27 for Q2 2025 and -0.49 for Q1 2025.